primary myelofibrosis: Myelofibrosis with myeloid metaplasia is a myeloproliferative disease with annual incidence of approximately 1 case per 100,000 individuals and age at diagnosis around 60 (an increased prevalence is noted in Ashkenazi Jews). Clinical manifestations depend on the type of blood cell affected and may include anemia, pallor, splenomegaly, hypermetabolic state, petechiae, ecchymosis, bleeding, lymphadenopathy, hepatomegaly, portal hypertension.
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleNone |
520210 |
2. Check conditionsNone |
520210 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
3 out of 7 registries used, show all original rules. |
1336 |
4. Check minimum number of eventsNone |
1336 |
5. Include endpointsNone |
1336 |
6. Filter based on genotype QC (FinnGen only) |
1336 |
Control definitions (FinnGen only)
- Control exclude
- C3_CANCER, C3_CANCER_WIDE
Extra metadata
- First used in FinnGen datafreeze
- DF8
Essential (haemorrhagic) thrombocythaemia
based on the number of shared cases.
Similar with more cases:
Similar with less cases:
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 7386 | 4434 | 2920 |
| Only index persons | 6776 | 4112 | 2664 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.11 | 0.13 | 0.08 |
| Only index persons | 0.13 | 0.15 | 0.10 |
| Median age at first event (years) | |||
| Whole population | 65.45 | 66.09 | 64.42 |
| Only index persons | 64.72 | 65.35 | 63.73 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 1336 | 784 | 552 |
| Unadjusted period prevalence (%) | 0.26 | 0.27 | 0.24 |
| Median age at first event (years) | 63.00 | 62.00 | 64.42 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 1205
- Matched controls
- 12051
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
XW000
NOMESCO Finland
Bone marrow biopsy
52.4
323.0
430
126
D47.3
ICD-10 Finland
Essential (haemorrhagic) thrombocythaemia
+∞
323.0
1148
*
9962/3-C42.1
ICD-O-3
Essential thrombocythemia of bone marrow
+∞
323.0
360
*
L01XX05
ATC
hydroxycarbamide; oral
691.6
323.0
758
29
D75.2
ICD-10 Finland
Essential thrombocytosis
661.7
323.0
522
14
117
Kela drug reimbursment
Leukaemia and other malignant diseases of the blood and bone marrow, and malignant diseases of the lymphatic tissue
780.6
323.0
841
36
D45
ICD-10 Finland
Polycythaemia vera
72.4
176.2
200
33
TNE25
NOMESCO Finland
Drill biopsy of bone marrow, pelvis
119.4
163.1
174
17
L01XX35
ATC
anagrelide; oral
872.6
159.3
153
*
L03AB05
ATC
interferon alfa-2b; parenteral
283.4
126.6
127
5
D47.1
ICD-10 Finland
Chronic myeloproliferative disease
200.6
123.0
126
7
D75.9
ICD-10 Finland
Disease of blood and blood-forming organs, unspecified
65.0
106.4
123
21
L03AB04
ATC
interferon alfa-2a; parenteral
785.5
76.1
74
*
9961/3-C42.1
ICD-O-3
Primary myelofibrosis of bone marrow
335.1
63.0
63
*
9960/3-C42.1
ICD-O-3
Myeloproliferative neoplasm, NOS, of bone marrow
157.6
57.4
60
*
JN1AE
NOMESCO Finland
Ultrasound examination of upper part of abdomen
4.7
51.1
190
462
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
3.8
51.1
247
768
8140/3-C61.9
ICD-O-3
Adenocarcinoma, NOS, of prostate gland
518.6
50.8
50
*
TPH00
NOMESCO Finland
Phlebotomy
33.7
49.1
64
20
C61
ICD-10 Finland
Malignant neoplasm of prostate
108.6
48.2
52
5
8090/3-C44.9
ICD-O-3
Basal cell carcinoma, NOS, of skin, NOS
+∞
47.2
45
*
SPAT1074
SPAT
Venesection
35.2
41.9
54
16
130
Kela drug reimbursment
Malignant tumour
+∞
40.9
39
*
C44.31
ICD-10 Finland
Basocellular carcinoma of the skin on another or unspecified part of the face
37.9
40.3
51
14
D47.2
ICD-10 Finland
Monoclonal gammopathy of undetermined significance (MGUS)
17.3
40.2
64
39
115
Kela drug reimbursment
Breast cancer
+∞
39.8
38
*
PJA12
NOMESCO Finland
Sentinel node biopsy
357.0
35.1
35
*
9950/3-C42.1
ICD-O-3
Polycythemia vera of bone marrow
48.2
34.9
42
9
D47.9
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour of lymphoid, haematopoietic and related tissue, unspecified
48.2
34.9
42
9
C50.41
ICD-10 Finland
Malignant tumor of the upper outer quadrant of the mammary gland, ductal tumor
+∞
32.4
31
*
WW500
NOMESCO Finland
Blood transfusion
9.3
31.7
67
76
212
Kela drug reimbursment
Gout
10.2
31.4
63
65
174
Kela drug reimbursment
Ruxolitinib
320.7
31.0
31
*
A04AA02
ATC
granisetron; systemic, transdermal
164.1
30.8
32
*
M04AA01
ATC
allopurinol; systemic
2.8
30.7
224
910
H02AB02
ATC
dexamethasone; systemic
11.9
30.3
56
49
NEA10
NOMESCO Finland
Exploration of soft tissue of pelvis, percutaneous
60.0
30.2
35
6
8500/3-C50.9
ICD-O-3
Infiltrating duct carcinoma, NOS, of breast, NOS
+∞
28.2
27
*
L03AA04
ATC
NA
287.7
27.9
28
*
GD1AA
NOMESCO Finland
Thorax X-ray examination
2.0
27.7
553
3601
B01AB05
ATC
enoxaparin; parenteral
2.1
27.7
385
2163
R79.8
ICD-10 Finland
Other specified abnormal findings of blood chemistry
21.7
26.2
38
18
374
Kela drug reimbursment
Ruxolitinib
265.9
25.8
26
*
116
Kela drug reimbursment
Prostate cancer
+∞
25.1
24
*
B99
ICPC
Blood/lymph/spleen disease other
26.0
24.0
33
13
B01AC14
ATC
[U] anagrelide; oral
+∞
24.0
23
*
L01EJ01
ATC
ruxolitinib; oral
223.8
21.7
22
*
HAB40
NOMESCO Finland
Wedge excision of mammary gland
19.8
20.9
31
16
HAC20
NOMESCO Finland
Total mastectomy
213.4
20.6
21
*
L01XE18
ATC
[U] ruxolitinib; oral
213.4
20.6
21
*
QAE10
NOMESCO Finland
Excision of other lesion extending through all layers of skin in head or neck
4.2
20.0
78
196
ZX012
NOMESCO Finland
Radiotherapy with large shaped fields - isocentric therapy
74.7
19.7
22
*
WD125
NOMESCO Finland
Demanding cystostatic therapy of methastized malignancy
203.1
19.6
20
*
C44.32
ICD-10 Finland
Spinocellular carcinoma of the skin on another or unspecified part of the face
+∞
18.8
18
*
WD105
NOMESCO Finland
Cystostatic therapy of methastized malignancy
+∞
18.8
18
*
L01BC06
ATC
capecitabine; oral
+∞
18.8
18
*
HA003
NOMESCO Finland
Radiotherapy after partial ablation of mammary gland
+∞
18.8
18
*
C90.0
ICD-10 Finland
Multiple myeloma
+∞
18.8
18
*
8090/3-C44.3
ICD-O-3
Basal cell carcinoma, NOS, of skin of other and unspecified parts of face
+∞
18.8
18
*
Z51.5
ICD-10 Finland
Palliative care
6.3
18.0
48
79
8070/3-C44.9
ICD-O-3
Squamous cell carcinoma, NOS, of skin, NOS
+∞
17.7
17
*
PJD52
NOMESCO Finland
Block dissection of axillary lymph nodes
+∞
17.7
17
*
A04AA01
ATC
ondansetron; systemic, rectal
5.4
17.2
52
100
D75.8
ICD-10 Finland
Other specified diseases of blood and blood-forming organs
64.2
16.8
19
*
C92.0
ICD-10 Finland
Acute myeloblastic leukaemia [AML]
+∞
16.7
16
*
L02BB03
ATC
bicalutamide; oral
+∞
16.7
16
*
L03AA02
ATC
filgrastim; parenteral
91.3
16.6
18
*
WF002
NOMESCO Finland
Radical radiotherapy
40.7
16.4
20
5
YG1BD
NOMESCO Finland
Extensive CT examination of thorax for dose design of radiotherapy
+∞
15.7
15
*
L03AA13
ATC
pegfilgrastim; parenteral
+∞
15.7
15
*
WB113
NOMESCO Finland
Multiple adjuvant cytostatic therapy
+∞
15.7
15
*
C50.99
ICD-10 Finland
Breast, unspecified
+∞
15.7
15
*
XX7BT
NOMESCO Finland
Radioactive phosphorus therapy
86.2
15.6
17
*
TQX10
NOMESCO Finland
Biopsy of skin and subcutaneous tissue
2.7
15.6
113
448
B03XA02
ATC
darbepoetin alfa; parenteral
6.6
15.3
39
61
D69.6
ICD-10 Finland
Thrombocytopenia, unspecified
6.2
15.1
40
66
T81.0
ICD-10 Finland
Haemorrhage and haematoma complicating a procedure, not elsewhere classified
3.0
14.7
88
309
C91.1
ICD-10 Finland
Chronic lymphocytic leukaemia of B-cell type
+∞
14.6
14
*
C79.8
ICD-10 Finland
Secondary malignant neoplasm of other specified sites
+∞
14.6
14
*
JN4BD
NOMESCO Finland
Extensive body CT
3.1
14.5
80
268
Y77
ICPC
Malignant neoplasm prostate
151.7
14.5
15
*
D47.0
ICD-10 Finland
Histiocytic and mast cell tumours of uncertain and unknown behaviour
151.7
14.5
15
*
C44.51
ICD-10 Finland
Basocellular carcinoma of the skin on the torso
27.5
14.3
19
7
R79.9
ICD-10 Finland
Abnormal finding of blood chemistry, unspecified
9.5
14.0
28
30
B01AB10
ATC
tinzaparin; parenteral
3.3
13.8
70
221
B03XA01
ATC
erythropoietin; parenteral
13.8
13.7
23
17
WZC00
NOMESCO Finland
Planning of intervention or health care consultation
1.8
13.7
298
1893
C20.91
ICD-10 Finland
Malignant tumor of the rectum invasive carcinoma
+∞
13.6
13
*
8140/3-C20.9
ICD-O-3
Adenocarcinoma, NOS, of rectum, NOS
+∞
13.6
13
*
C50.40
ICD-10 Finland
Malignant tumor of the upper outer quadrant of the mammary gland, no histological veryfication
+∞
13.6
13
*
ZX120
NOMESCO Finland
Intravenous
2.6
13.4
99
399
WD115
NOMESCO Finland
Multiple cystostatic therapy of methastized malignancy
+∞
12.5
12
*
2387B
ICD-9 Finland
Neoplasm of uncertain behaviour of other and unspecified sites and tissues, Other lymphatic and haematopoietic tissues[THROMBOCYTHAEMIA IDIOPATHICA]
+∞
12.5
12
*
8090/3-C44.5
ICD-O-3
Basal cell carcinoma, NOS, of skin of trunk
+∞
12.5
12
*
9861/3-C42.1
ICD-O-3
Acute myeloid leukemia, NOS, of bone marrow
+∞
12.5
12
*
R50.9
ICD-10 Finland
Fever, unspecified
2.1
12.5
143
716
C44.30
ICD-10 Finland
Malignant tumor of the skin on another or unspecified part of the face without histology
131.3
12.5
13
*
A03FA01
ATC
metoclopramide; systemic, rectal
2.1
12.4
153
790
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
1.6
12.2
352
2411
XW4XT
NOMESCO Finland
Biopsy of other inner organ with radiological guidance guidance
37.9
12.2
15
*
XX3DW
NOMESCO Finland
Time consuming IT work
3.0
11.6
68
238
WF049
NOMESCO Finland
Radiotherapy of metastasis
65.6
11.6
13
*
R04.0
ICD-10 Finland
Epistaxis
2.3
11.5
104
466
KEC00
NOMESCO Finland
Retropubic radical prostatectomy
+∞
11.5
11
*
L57.0
ICD-10 Finland
Actinic keratosis
2.3
10.7
104
485
WD405
NOMESCO Finland
Simple antiboidy therapy of methastized malignancy
60.5
10.6
12
*
R4110
NOMESCO Finland
Physiotherapy
1.6
10.6
291
1954
D69.1
ICD-10 Finland
Qualitative platelet defects
+∞
10.4
10
*
C50
ICD-10 Finland
Malignant neoplasm of breast
+∞
10.4
10
*
C64.88
ICD-10 Finland
Other malignant neoplasm of kidney, except renal pelvis
+∞
10.4
10
*
C44.11
ICD-10 Finland
Basocellular carcinoma of the skin of the eyelids including the corner of the eye
+∞
10.4
10
*
8500/3-C50.4
ICD-O-3
Infiltrating duct carcinoma, NOS, of upper-outer quadrant of breast
+∞
10.4
10
*
C50.90
ICD-10 Finland
Malignant tumor in other or unspecified location in mammary gland without histology
+∞
10.4
10
*
D05.1
ICD-10 Finland
Intraductal carcinoma in situ
+∞
10.4
10
*
B74
ICPC
Malignant neoplasm blood other
+∞
10.4
10
*
A02BC02
ATC
pantoprazole; systemic
1.5
10.4
728
6076
J01MA12
ATC
levofloxacin; systemic
1.8
10.2
201
1225
TPH07
NOMESCO Finland
Cathetrisation of artery
2.2
10.1
102
481
QBA25
NOMESCO Finland
Destruction of lesion of skin of trunk
8.2
9.8
21
26
TPH04
NOMESCO Finland
Cathetrisation of vein
1.7
9.7
223
1425
YX9AD
NOMESCO Finland
Other CT eamination for dose design of radiotherapy
55.4
9.7
11
*
A49.9
ICD-10 Finland
Bacterial infection, unspecified
2.1
9.6
116
593
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
1.5
9.4
357
2588
2387X
ICD-9 Finland
Neoplasm of uncertain behaviour of other and unspecified sites and tissues, Other lymphatic and haematopoietic tissues[STATUS LYMPHO- ET MYELOPROLIFERATIVUS NUD]
100.7
9.4
10
*
XW000
SPAT
NA
100.7
9.4
10
*
L02BA01
ATC
tamoxifen; oral
30.3
9.4
12
*
WX408
NOMESCO Finland
General anesthesy, balanced
1.6
9.4
257
1722
WB203
NOMESCO Finland
Simple adjuvant hormone therapy of malignancy
+∞
9.4
9
*
C50.51
ICD-10 Finland
Malignant tumor of the lower outer quadrant of the mammary gland, ductal tumor
+∞
9.4
9
*
C67.8
ICD-10 Finland
Malignant neoplasm: Overlapping lesion of bladder
+∞
9.4
9
*
C78.7
ICD-10 Finland
Secondary malignant neoplasm of liver and intrahepatic bile duct
+∞
9.4
9
*
KEC01
NOMESCO Finland
Percutaneous endoscopic radical prostatectomy
+∞
9.4
9
*
PJ5AN
NOMESCO Finland
Localisation of sentinell lymphnode with isotope imaging
+∞
9.4
9
*
D04.3
ICD-10 Finland
Carcinoma in situ: Skin of other and unspecified parts of face
5.6
9.4
26
47
D69.3
ICD-10 Finland
Idiopathic thrombocytopenic purpura
8.1
9.4
20
25
L02BG04
ATC
letrozole; oral
6.8
9.1
22
33
JN4AD
NOMESCO Finland
Body CT examination
3.1
9.0
49
165
ZX112
NOMESCO Finland
Subcutaneous
9.1
9.0
18
20
HA1AE
NOMESCO Finland
Ultrasound examination of mammary glands
3.6
9.0
39
111
D72.8
ICD-10 Finland
Other specified disorders of white blood cells
8.0
8.9
19
24
FB1BD
NOMESCO Finland
Extensive CT examination of arteria pulmonalis
2.2
8.8
89
424
QDB10
NOMESCO Finland
Major dressing of wound of skin of lower limb
2.5
8.8
67
278
ZZR00
NOMESCO Finland
Flap of skin
7.7
8.7
19
25
N02AA05
ATC
oxycodone; systemic
1.9
8.6
130
727
B28
ICPC
Limited function/disability (B)
10.1
8.5
16
16
TNE20
NOMESCO Finland
Bone marrow aspiration, pelvis
20.2
8.5
12
6
G45.9
ICD-10 Finland
Transient cerebral ischaemic attack, unspecified
2.0
8.4
114
612
GDC01
NOMESCO Finland
Thoracoscopic lobectomy of lung
90.6
8.4
9
*
C20.90
ICD-10 Finland
Malignant tumor of the rectum without histology
90.6
8.4
9
*
X76
ICPC
Malignant neoplasm breast female
+∞
8.3
8
*
C83.31
ICD-10 Finland
Diffuse lymphoma with large B cells
+∞
8.3
8
*
C92.1
ICD-10 Finland
Chronic myeloid leukaemia [CML], BCR/ABL-positive
+∞
8.3
8
*
C50.42
ICD-10 Finland
Malignant tumor of the upper outer quadrant of the mammary gland, lobular tumor
+∞
8.3
8
*
DAB10
NOMESCO Finland
Partial excision of auricle
+∞
8.3
8
*
WD135
NOMESCO Finland
Demanding cystostatic therapy of methastized malignancy
+∞
8.3
8
*
C73.91
ICD-10 Finland
Papillary carcinoma of the thyroid gland (thyroid gland)
+∞
8.3
8
*
8120/3-C67.9
ICD-O-3
Transitional cell carcinoma, NOS, of bladder, NOS
+∞
8.3
8
*
S77
ICPC
Malignant neoplasm of skin
33.6
8.1
10
*
D75.0
ICD-10 Finland
Familial erythrocytosis
33.6
8.1
10
*
NK6AN
NOMESCO Finland
Total body bone isotope imaging
11.8
8.1
14
12
D73.5
ICD-10 Finland
Infarction of spleen
22.2
8.0
11
5
J01CR02
ATC
amoxicillin and beta-lactamase inhibitor; systemic
1.4
7.9
514
4133
R51.80
ICD-10 Finland
Headache
1.8
7.7
147
883
S97
ICPC
Chronic ulcer skin
2.3
7.7
71
323
WB103
NOMESCO Finland
Simple adjuvant cytostatic therapy
45.2
7.7
9
*
J01DB01
ATC
cefalexin; oral
1.5
7.7
895
8000
O99.1
ICD-10 Finland
Other diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism complicating pregnancy, childbirth and the puerperium
25.2
7.6
10
*
Z04.8
ICD-10 Finland
Examination and observation for other specified reasons
1.8
7.5
135
797
B01AA03
ATC
warfarin; systemic
1.6
7.4
238
1650
WF003
NOMESCO Finland
Adjuvant radiotherapy
80.5
7.4
8
*
ZX090
NOMESCO Finland
Other technic of radiotherapy
80.5
7.4
8
*
D75
ICD-10 Finland
Other diseases of blood and blood-forming organs
80.5
7.4
8
*
WF004
NOMESCO Finland
Palliative radiotherapy
80.5
7.4
8
*
I70.2
ICD-10 Finland
Atherosclerosis of arteries of extremities
1.9
7.4
115
647
C03CA01
ATC
furosemide; systemic
1.5
7.4
337
2524
L97
ICD-10 Finland
Ulcer of lower limb, not elsewhere classified
2.6
7.3
52
209
L02AE02
ATC
leuprorelin; implant, parenteral
6.9
7.3
17
25
C54.11
ICD-10 Finland
Adenocarcinoma of the endometrium
+∞
7.3
7
*
YG1AD
NOMESCO Finland
CT examination of thorax for dose design of radiotherapy
+∞
7.3
7
*
C44.21
ICD-10 Finland
Basocellular carcinoma of the skin of the outer ear and the outer ear canal
+∞
7.3
7
*
C34.12
ICD-10 Finland
Malignant tumor of the anterior, bronchial or pulmonary adenocarcinoma
+∞
7.3
7
*
YL1BD
NOMESCO Finland
Extensive CT examination of pelvis for dose design of radiotherapy
+∞
7.3
7
*
8090/3-C44.4
ICD-O-3
Basal cell carcinoma, NOS, of skin of scalp and neck
+∞
7.3
7
*
C50.81
ICD-10 Finland
Overall malignant tumor of the mammary gland, ductal tumor
+∞
7.3
7
*
C67.9
ICD-10 Finland
Malignant neoplasm: Bladder, unspecified
+∞
7.3
7
*
8097/3-C44.9
ICD-O-3
Basal cell carcinoma, nodular of skin, NOS
+∞
7.3
7
*
ZX080
NOMESCO Finland
Image guided radiotherapy
+∞
7.3
7
*
WX700
NOMESCO Finland
Respiratory and circulatory monitoring
1.7
7.2
171
1094
HA1AA
NOMESCO Finland
X-ray mammography
2.8
7.2
43
156
308
Kela drug reimbursment
Alprostadil, sildenafil and combination product containing aviptadil and phentolamine
20.1
7.1
10
5
L98.4
ICD-10 Finland
Chronic ulcer of skin, not elsewhere classified
3.6
7.1
30
85
D38.1
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Trachea, bronchus and lung
4.7
7.0
22
47
R2130
NOMESCO Finland
Counselling and guidance which enhance independent living
2.0
6.9
80
407
I26.0
ICD-10 Finland
Pulmonary embolism with mention of acute cor pulmonale
3.5
6.8
30
88
I26.9
ICD-10 Finland
Pulmonary embolism without mention of acute cor pulmonale
2.3
6.8
60
270
Z03.89
ICD-10 Finland
Observation for other suspected diseases and conditions
1.7
6.7
141
874
FM1AE
NOMESCO Finland
Standard cardiac ultrasound examination
1.6
6.6
200
1364
N02BE01
ATC
paracetamol; systemic, rectal
1.5
6.6
967
8862
I81
ICD-10 Finland
Portal vein thrombosis
12.3
6.6
11
9
XF603
NOMESCO Finland
Direct intraarterial blood pressure measurement
3.1
6.5
33
108
C44.41
ICD-10 Finland
Basocellular carcinoma of the skin of the scalp and neck
70.2
6.4
7
*
Z01.8
ICD-10 Finland
Other specified special examinations
1.5
6.3
227
1611
QAE99
NOMESCO Finland
Other excision or repair surgery of skin and subcutaneous tissue in head and neck
4.2
6.3
22
53
WZC20
NOMESCO Finland
Multidisciplinary treatment meeting
3.6
6.3
26
73
KE1AT
NOMESCO Finland
Biopsy of prostata with ultrasoudnguidance
3.3
6.3
29
89
UJF32
NOMESCO Finland
Coloscopy
1.5
6.3
273
2014
C67.2
ICD-10 Finland
Malignant neoplasm: Lateral wall of bladder
+∞
6.3
6
*
C50.91
ICD-10 Finland
Malignant tumor in another specified localization in ductal mammary gland
+∞
6.3
6
*
C50.49
ICD-10 Finland
Malignant tumor of the upper outer quadrant of the mammary gland, other or undeterminated histology
+∞
6.3
6
*
8380/3-C54.1
ICD-O-3
Endometrioid adenocarcinoma, NOS, of endometrium
+∞
6.3
6
*
8520/3-C50.9
ICD-O-3
Lobular carcinoma, NOS, of breast, NOS
+∞
6.3
6
*
C50.21
ICD-10 Finland
Malignant tumor of the upper inner quadrant of the mammary gland,ductal tumor
+∞
6.3
6
*
9823/3-C42.1
ICD-O-3
B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma of bone marrow
+∞
6.3
6
*
A04AD12
ATC
aprepitant; systemic
+∞
6.3
6
*
WB123
NOMESCO Finland
Demanding adjuvant cytostatic therapy
+∞
6.3
6
*
L02BG03
ATC
anastrozole; oral
26.8
6.2
8
*
R60.0
ICD-10 Finland
Localized oedema
1.7
6.2
125
768
N02AB03
ATC
fentanyl; nasal, sublingual, transdermal
3.1
6.1
30
97
KCD02
NOMESCO Finland
Transurethral resection of bladder
8.6
6.1
12
14
WZC30
NOMESCO Finland
Teaching
1.8
6.0
93
526
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
397
116
48.27
307.65
1.3
1.5
—
—
—
0
0
971
992
33.17
307.65
9.6
2.5
281.9
235.4
u/l
14.18
939
923
457
118
58.34
307.65
1.0
1.0
—
—
—
0
0
664
1190
10.11
307.65
3.6
2.2
1.8
1.8
%
0.21
586
1055
335
175
25.21
307.65
1.3
1.2
32.0
20.1
u/l
0.71
297
150
1090
4620
8.38
246.48
17.0
5.5
1.0
0.7
%
32.73
1061
4257
1099
4752
8.40
241.14
17.1
5.5
2.7
2.9
%
4.85
1071
4375
1106
4884
8.35
234.61
17.7
5.6
25.8
27.6
%
6.59
1078
4489
1147
5247
9.38
234.01
15.9
5.4
1.8
1.9
e9/l
0.29
1078
4561
1096
4840
8.04
231.05
16.3
5.5
59.9
57.6
%
9.41
1067
4475
1148
5321
9.23
228.66
17.0
5.5
0.2
0.2
e9/l
0.58
1071
4626
543
1335
6.17
223.31
2.7
2.4
23.9
23.0
%
0.67
480
1127
1167
5714
9.24
211.72
22.2
6.3
4.7
4.3
e9/l
2.56
1097
4903
549
1449
5.73
206.43
2.6
2.3
2.3
2.3
g/l
0.27
524
1336
797
2895
5.35
203.45
4.3
2.4
1867.0
7139.9
umol/l
4.39
736
2463
570
1603
5.46
197.89
2.7
2.3
14.0
13.1
umol/l
2.02
546
1468
1035
5104
5.56
168.37
9.0
3.6
11.2
11.7
umol/l
0.53
1003
4760
199
257
8.92
148.17
2.6
2.1
3.3
3.5
g/l
1.20
190
237
847
4446
3.47
104.98
4.0
2.7
128.5
119.3
ug/l
0.52
791
4048
211
452
5.36
95.08
1.8
1.6
1.1
1.5
g/l
8.05
178
391
102
99
11.07
93.21
9.6
2.7
1.8
1.3
%
0.56
73
70
1191
8138
5.27
91.83
15.5
5.3
80.2
75.6
u/l
3.00
1162
7506
158
270
6.50
90.33
2.2
1.9
94.3
87.9
%
2.57
131
257
599
2748
3.14
89.40
2.7
2.2
3.6
3.0
mg/l
3.47
517
2328
889
5323
3.00
78.18
7.4
5.3
1.2
1.2
mmol/l
0.01
747
4501
807
4814
2.71
67.44
6.6
4.8
1.2
1.2
mmol/l
3.61
742
4248
101
174
6.20
56.81
6.5
3.2
61.0
58.1
%
1.41
101
174
118
239
5.32
55.86
3.4
2.6
1.3
1.6
mg/l
4.40
113
208
119
243
5.28
55.81
2.7
2.1
173.6
191.5
%
1.11
112
229
775
4865
2.41
53.09
2.4
2.0
91.1
94.4
pmol/l
1.14
441
2397
724
4439
2.38
51.95
5.5
3.6
35.8
35.6
g/l
0.39
679
4059
63
70
9.40
51.94
9.0
2.6
64.0
53.4
%
2.09
31
44
525
2798
2.44
51.82
1.8
1.5
21.3
20.8
nmol/l
0.26
470
2335
110
231
5.10
49.88
1.7
1.5
—
—
—
0
0
264
1054
2.88
46.47
4.0
2.1
7.2
7.5
umol/l
0.08
241
905
318
1496
2.48
39.70
3.0
2.5
0.8
0.8
mmol/l
1.21
304
1377
215
858
2.79
37.34
2.4
1.6
66.2
67.3
g/l
1.15
192
768
329
1634
2.34
35.98
2.7
1.9
31.3
29.8
s
5.16
309
1577
866
6368
2.02
32.09
5.5
4.2
6.5
6.8
mmol/l
4.22
835
5938
403
2274
2.11
31.57
2.0
1.6
1.1
1.2
mg/l
0.25
311
1737
30
26
11.78
29.22
6.8
2.0
—
—
—
0
0
106
326
3.45
28.64
2.6
1.4
0.1
0.0
g/l
0.47
92
299
101
308
3.47
27.64
2.3
1.4
0.0
0.0
g/l
0.00
87
282
100
304
3.47
27.50
2.3
1.4
0.0
0.0
g/l
0.00
87
281
264
1341
2.21
26.55
3.9
4.6
1.1
1.0
mmol/l
1.89
246
1221
385
2267
1.98
25.99
1.9
1.8
1042.8
1177.3
nmol/l
2.27
277
1712
110
370
3.15
25.68
2.6
1.4
1.2
0.4
g/l
1.74
95
319
117
412
3.02
25.24
2.5
1.4
3.1
3.1
g/l
0.01
92
321
497
3216
1.87
25.05
4.1
2.6
34.0
33.3
u/l
0.10
476
3050
105
350
3.17
24.88
2.3
1.4
38.9
37.8
g/l
0.94
90
294
116
411
3.00
24.74
2.2
1.4
10.9
10.6
g/l
0.38
97
346
121
441
2.92
24.54
2.4
1.4
3.5
3.9
g/l
1.80
93
314
121
441
2.92
24.54
2.4
1.4
—
—
—
0
0
121
441
2.92
24.54
2.4
1.4
6.8
7.5
g/l
3.36
94
329
1015
8229
1.97
24.35
5.1
4.2
12.8
12.3
mm/h
0.43
947
7581
95
320
3.12
22.09
2.9
1.4
33.8
50.9
mg/l
0.47
87
258
95
321
3.11
21.98
2.9
1.4
72.9
42.9
mg/l
0.41
87
260
92
305
3.17
21.98
3.0
1.4
1.2
1.4
ratio
—
10
28
1223
10802
2.56
21.19
25.9
12.6
20.7
23.2
mg/l
2.02
1024
8360
1051
8790
1.92
20.71
36.6
15.2
15.0
13.7
%
66.74
1046
8562
153
685
2.39
20.44
2.4
2.2
10.1
10.8
g/l
1.22
136
622
24
5
48.81
20.20
1.0
1.0
—
—
—
0
0
324
1973
1.85
18.89
3.4
2.2
2.4
2.4
mmol/l
0.47
279
1687
497
3431
1.71
18.80
2.9
2.1
2.3
2.4
mmol/l
1.63
430
2832
31
51
6.20
18.16
2.2
1.3
—
—
—
0
0
31
51
6.20
18.16
2.2
1.3
—
—
—
0
0
127
569
2.36
16.88
2.8
1.4
4.4
3.8
ug/l
0.23
90
436
421
2855
1.69
16.57
3.7
2.9
0.4
0.4
e6/l
0.01
314
2154
284
1722
1.82
16.55
1.9
1.8
—
—
—
0
0
354
2304
1.73
16.13
4.3
2.0
—
—
—
0
0
143
692
2.19
15.81
1.7
1.5
—
—
—
0
0
168
871
2.06
15.54
4.4
6.1
9.5
10.3
mmol/l
0.69
159
824
607
4598
1.59
14.90
7.9
3.5
—
—
—
0
0
14
0
+∞
14.61
2.5
0.0
—
—
—
0
0
1098
9650
1.77
14.19
32.2
14.0
38.4
39.5
%
3.05
723
6427
49
147
3.42
13.78
4.3
5.6
1502.3
338.6
iu/ml
—
6
21
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
75
291
2.67
13.50
3.0
2.8
0.3
0.4
u/ml
2.44
43
175
671
5316
1.53
12.77
4.9
5.1
0.0
0.0
estimate
0.00
157
909
1242
11444
2.21
12.76
26.5
15.2
139.5
139.7
mmol/l
2.03
1221
11125
1244
11472
2.23
12.71
28.4
15.3
4.0
4.0
mmol/l
1.98
1222
11135
46
140
3.37
12.67
1.2
1.2
1.6
3.5
u/ml
0.51
18
40
676
5372
1.52
12.63
3.6
3.8
0.0
0.0
estimate
1.08
155
891
152
818
1.97
12.60
3.5
2.9
1.2
1.2
mmol/l
0.16
128
679
328
2237
1.62
12.00
3.9
3.9
1004.6
481.6
ng/l
0.30
263
1813
664
5295
1.51
11.96
3.6
3.7
0.0
0.0
estimate
0.00
157
908
201
1209
1.78
11.73
1.8
1.7
—
—
—
0
0
251
1611
1.69
11.61
3.3
2.7
2.0
2.8
e6/l
0.68
122
860
43
134
3.28
11.43
1.2
1.2
5.2
6.0
u/ml
0.08
20
57
199
1206
1.76
11.30
1.8
1.8
—
—
—
0
0
125
656
2.00
11.11
1.6
1.6
—
—
—
0
0
153
877
1.84
10.43
2.2
2.1
32.5
36.1
u/l
0.58
134
732
464
3522
1.49
10.17
3.2
2.9
2754.6
1354.3
ng/l
2.30
409
2986
112
586
1.99
10.04
3.1
2.8
4.3
4.5
pmol/l
1.61
89
501
313
2191
1.56
10.03
2.9
2.4
5.4
6.1
e6/l
0.37
279
1900
280
1911
1.59
10.01
1.5
1.3
2.4
2.6
g/l
0.70
162
1082
18
32
5.69
9.76
1.5
1.9
—
—
—
0
0
1154
10561
1.68
9.57
5.2
4.2
1.3
1.3
mmol/l
0.88
1092
9550
1244
11639
2.00
9.55
22.8
9.1
24.9
25.3
u/l
0.31
1224
11131
41
139
3.01
9.52
1.0
1.1
—
—
—
0
0
137
785
1.83
9.34
2.1
1.9
0.2
0.2
g/l
0.10
120
715
16
27
5.99
9.13
1.4
1.0
69.6
86.5
%
—
7
11
13
7
18.74
8.94
1.6
1.9
—
—
—
0
0
256
1758
1.56
8.82
3.1
2.5
0.9
1.5
e6/l
1.20
124
1006
146
871
1.76
8.70
6.4
5.4
1.4
1.4
mmol/l
0.01
141
838
15
25
6.06
8.66
1.1
1.3
—
—
—
0
0
10
10
10.07
8.65
1.5
1.1
—
—
—
0
0
1123
10276
1.58
8.52
26.4
11.6
77.4
77.3
ml/min/173m2
0.05
982
8251
780
6666
1.41
8.41
3.4
2.9
57.5
46.2
u/l
3.07
745
6127
15
26
5.82
8.34
1.5
1.0
69.3
90.7
%
—
7
11
822
7118
1.40
8.02
4.7
4.6
8081.8
2565.8
e6/l
—
8
108
160
1005
1.67
7.90
2.9
3.0
5.8
5.8
kpa
0.35
155
977
39
144
2.76
7.81
1.1
1.3
116.3
111.2
u/ml
—
7
29
46
186
2.53
7.72
1.6
1.5
—
—
—
0
0
47
194
2.47
7.56
1.6
1.5
—
—
—
0
0
158
1001
1.66
7.55
2.9
3.0
1.3
2.1
mmol/l
1.22
130
806
42
165
2.60
7.48
1.1
1.2
—
—
—
0
0
1106
10168
1.51
7.35
5.4
4.8
2.0
2.1
mu/l
0.13
1035
9215
36
134
2.73
7.13
1.5
1.5
—
—
—
0
0
58
271
2.19
7.06
1.7
2.1
17.8
12.0
mg/l
0.86
52
248
39
154
2.58
6.89
1.1
1.2
266.9
262.6
u/ml
0.03
29
88
16
36
4.49
6.71
1.6
1.8
15.4
12.7
%
—
7
15
42
175
2.45
6.65
1.6
1.5
—
—
—
0
0
26
84
3.14
6.61
1.3
1.5
143377.2
106962.9
e6/l
0.11
19
50
141
900
1.63
6.54
3.2
2.3
58.9
65.4
ml/min/173m2
1.51
82
351
450
3623
1.37
6.42
2.0
2.1
136.5
228.5
u/l
2.97
420
3392
1167
10930
1.54
6.29
5.7
4.7
1.4
1.5
mmol/l
19.46
1109
9973
147
959
1.60
6.24
1.9
1.8
439.5
360.7
nmol/l
3.50
135
861
941
8498
1.36
6.09
4.3
4.0
15.1
14.9
pmol/l
0.96
852
7666
72
395
1.87
5.69
1.7
1.7
0.9
1.8
ug/l
1.27
65
346
1171
11020
1.51
5.69
5.8
4.7
4.2
4.6
mmol/l
33.16
1117
10120
15
38
3.98
5.45
2.4
4.6
—
—
—
0
0
26
95
2.77
5.38
1.3
1.5
1210.3
1850.5
e6/l
0.77
20
70
1190
11265
1.52
5.31
6.3
5.3
2.4
2.7
mmol/l
23.09
1136
10300
154
1064
1.51
5.07
3.9
3.1
—
—
—
0
0
9
9
10.06
5.03
1.7
1.9
—
—
—
0
0
168
1188
1.47
4.94
7.3
6.2
0.7
1.2
mmol/l
0.81
129
918
28
112
2.53
4.89
2.5
1.7
16.5
51.9
u/ml
1.16
23
101
23
83
2.80
4.89
1.4
1.7
—
—
—
0
0
168
1196
1.46
4.77
7.4
6.1
13.3
11.6
kpa
1.73
161
1143
168
1196
1.46
4.77
7.4
6.1
5.0
5.1
kpa
0.63
163
1145
207
1532
1.42
4.77
28.3
27.3
1.4
1.4
inr
0.12
41
208
55
295
1.90
4.71
1.2
1.2
—
—
—
0
0
48
247
1.98
4.63
1.9
1.7
—
—
—
0
0
43
213
2.05
4.61
1.5
1.4
—
—
—
0
0
43
213
2.05
4.61
1.5
1.4
—
—
—
0
0
402
3315
1.30
4.57
2.6
2.3
55.2
58.7
u/l
1.06
362
3029
57
315
1.85
4.47
1.3
1.6
0.2
0.2
g/l
0.25
52
302
52
279
1.90
4.46
3.3
3.1
25.5
25.0
mmol/l
0.33
46
242
1252
12058
1.61
4.34
45.0
18.7
446.6
247.8
e9/l
223.13
1234
11688
35
164
2.16
4.34
1.6
1.3
—
—
—
0
0
1252
12064
1.60
4.25
44.8
18.7
4.2
4.5
e12/l
41.23
1231
11646
1252
12067
1.60
4.21
45.1
18.8
130.2
135.5
g/l
26.83
1241
11844
1252
12067
1.60
4.21
44.9
18.8
8.1
6.7
e9/l
13.49
1232
11654
56
315
1.81
4.17
2.3
3.0
—
—
—
0
0
530
4573
1.26
4.11
2.3
2.3
79.9
79.0
nmol/l
0.30
461
3998
481
4107
1.27
4.06
4.0
3.9
—
—
—
0
0
20
76
2.66
3.90
1.2
1.2
—
—
—
0
0
20
76
2.66
3.90
1.2
1.2
—
—
—
0
0
13
39
3.36
3.76
1.6
1.1
—
—
—
0
0
13
39
3.36
3.76
1.6
1.1
—
—
—
0
0
13
39
3.36
3.76
1.6
1.1
—
—
—
0
0
13
39
3.36
3.76
1.6
1.1
—
—
—
0
0
6
5
12.05
3.76
1.0
1.0
—
—
—
0
0
40
209
1.94
3.75
2.5
2.4
16.5
16.5
%
0.03
20
107
20
78
2.59
3.72
1.2
1.2
—
—
—
0
0
20
78
2.59
3.72
1.2
1.2
—
—
—
0
0
20
78
2.59
3.72
1.2
1.2
—
—
—
0
0
31
148
2.12
3.70
1.3
1.3
—
—
—
0
0
69
427
1.65
3.70
2.4
1.7
—
—
—
0
0
1149
10942
1.36
3.68
5.0
4.9
5.9
6.0
mmol/l
3.88
1047
9894
8
12
6.70
3.67
1.6
1.8
—
—
—
0
0
14
45
3.13
3.65
1.5
2.5
1061.5
1139.8
u/ml
0.05
14
45
70
440
1.62
3.54
1.7
1.9
38.5
39.1
u/l
0.08
59
375
54
319
1.72
3.45
1.1
1.1
—
—
—
0
0
50
290
1.75
3.41
1.6
1.7
—
—
—
0
0
54
322
1.71
3.35
1.1
1.1
—
—
—
0
0
1101
10461
1.30
3.27
6.2
6.3
37.9
40.4
mmol/mol
18.72
1034
9639
98
678
1.48
3.26
3.2
3.4
5.1
5.2
kpa
0.24
89
622
93
638
1.49
3.23
3.0
3.3
2.2
2.0
mmol/l
0.22
68
461
500
4378
1.23
3.20
4.2
3.8
37.8
77.1
ng/l
1.27
385
3129
63
397
1.62
3.18
2.1
1.6
—
—
—
0
0
30
151
2.01
3.16
1.6
1.4
—
—
—
0
0
6
8
7.53
3.05
1.7
1.3
—
—
—
0
0
20
87
2.32
3.01
1.5
1.3
—
—
—
0
0
24
113
2.14
3.01
1.5
1.3
—
—
—
0
0
5
5
10.03
2.98
2.0
1.6
1.8
2.6
%
—
5
5
10
30
3.35
2.91
1.0
1.4
—
—
—
0
0
24
115
2.11
2.89
4.4
3.4
—
—
—
0
0
25
122
2.07
2.88
1.4
1.4
—
—
—
0
0
337
2862
1.24
2.83
4.2
4.1
0.0
0.0
estimate
0.50
155
893
11
36
3.07
2.81
1.2
1.1
—
—
—
0
0
15
59
2.56
2.79
1.3
2.3
—
—
—
0
0
26
131
2.00
2.76
1.7
1.3
—
—
—
0
0
41
242
1.72
2.69
1.2
1.3
—
—
—
0
0
119
889
1.37
2.64
3.2
3.5
92.8
87.4
ng/l
0.26
104
764
138
1061
1.34
2.55
3.1
3.0
172.3
203.9
ng/l
0.86
131
977
23
115
2.02
2.51
1.5
1.5
—
—
—
0
0
26
137
1.92
2.47
1.0
1.4
281.8
309.1
pmol/l
0.16
19
104
17
76
2.25
2.44
1.6
1.2
—
—
—
0
0
17
76
2.25
2.44
1.6
1.2
—
—
—
0
0
17
76
2.25
2.44
1.6
1.2
—
—
—
0
0
20
97
2.08
2.38
1.5
1.3
—
—
—
0
0
268
2267
1.23
2.31
1.3
1.2
2.0
1.6
u/ml
0.19
34
604
14
59
2.39
2.29
1.4
1.5
—
—
—
0
0
7
20
3.51
2.05
1.1
1.1
—
—
—
0
0
12
50
2.41
2.03
1.4
1.4
—
—
—
0
0
647
5975
1.16
1.99
2.8
2.6
—
—
—
0
0
18
91
1.99
1.95
3.2
2.1
—
—
—
0
0
45
298
1.53
1.94
1.1
1.2
3.8
8.5
u/ml
—
5
53
8
27
2.97
1.93
1.8
1.1
—
—
—
0
0
8
27
2.97
1.93
1.8
1.1
—
—
—
0
0
8
27
2.97
1.93
1.8
1.1
—
—
—
0
0
83
619
1.36
1.92
1.6
1.5
—
—
—
0
0
8
28
2.87
1.86
1.0
1.3
—
—
—
0
0
10
40
2.51
1.83
1.5
1.5
—
—
—
0
0
10
40
2.51
1.83
1.5
1.5
—
—
—
0
0
53
743
0.70
1.78
1.5
1.8
—
—
—
0
0
5
13
3.86
1.71
1.8
1.5
—
—
—
0
0
14
69
2.04
1.65
1.3
1.6
1.0
1.0
g/l
0.12
14
69
11
49
2.26
1.63
1.4
1.2
—
—
—
0
0
347
3103
1.16
1.58
1.7
1.7
1.4
1.4
mmol/l
0.20
306
2574
50
355
1.42
1.58
1.3
1.9
—
—
—
0
0
11
52
2.12
1.44
1.2
1.2
—
—
—
0
0
141
1176
1.22
1.43
2.2
2.2
206.9
143.6
ug/g
0.54
115
916
31
205
1.52
1.41
1.3
1.3
—
—
—
0
0
9
40
2.26
1.40
3.7
1.4
—
—
—
0
0
17
96
1.78
1.39
1.5
1.2
41.6
53.0
u/l
0.70
11
70
19
112
1.71
1.35
1.3
1.2
—
—
—
0
0
10
47
2.14
1.34
1.4
1.4
—
—
—
0
0
12
61
1.98
1.33
1.2
1.7
—
—
—
0
0
26
168
1.56
1.32
1.2
1.1
—
—
—
0
0
19
113
1.69
1.32
1.2
1.2
—
—
—
0
0
8
34
2.36
1.29
1.6
1.2
88.9
117.7
%
—
8
29
5
18
2.78
1.28
1.6
1.3
—
—
—
0
0
19
114
1.68
1.28
1.3
1.2
—
—
—
0
0
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
10
48
2.09
1.28
1.2
1.2
—
—
—
0
0
83
664
1.27
1.25
1.3
1.2
122.8
127.9
iu/ml
0.04
24
267
19
116
1.65
1.21
1.2
1.2
—
—
—
0
0
19
116
1.65
1.21
1.2
1.2
—
—
—
0
0
5
19
2.64
1.21
1.0
1.1
—
—
—
0
0
14
78
1.80
1.21
1.1
1.1
—
—
—
0
0
15
86
1.75
1.19
1.1
1.2
—
—
—
0
0
356
3886
0.89
1.19
3.6
4.0
9.8
7.5
mg/mmol
0.42
206
2398
11
58
1.90
1.12
1.2
1.1
—
—
—
0
0
20
127
1.58
1.11
1.7
6.3
8.1
7.6
mmol/l
0.22
15
107
7
31
2.26
1.10
2.1
1.7
—
—
—
0
0
29
204
1.43
1.03
2.1
2.8
44.3
35.4
umol/l
0.41
23
175
5
23
2.18
0.98
3.4
3.7
—
—
—
0
0
18
116
1.56
0.96
1.2
1.2
—
—
—
0
0
90
752
1.21
0.96
2.5
2.4
32.9
22.8
au/ml
—
7
37
353
3809
0.90
0.95
2.9
3.1
6.9
7.2
mmol/l
0.86
291
3194
27
192
1.41
0.93
1.4
1.6
—
—
—
0
0
6
28
2.15
0.91
1.2
1.1
—
—
—
0
0
37
279
1.34
0.91
1.5
1.4
274.2
300.7
ug/g
0.36
24
159
60
484
1.25
0.90
1.2
1.3
—
—
—
0
0
167
1483
1.14
0.87
1.5
1.4
—
—
—
0
0
211
1903
1.13
0.87
1.2
1.3
20.6
39.1
iu/ml
4.43
60
613
20
137
1.47
0.84
1.3
1.3
—
—
—
0
0
6
32
1.88
0.82
1.2
1.8
—
2024630.0
—
0
5
10
58
1.73
0.79
2.3
2.4
—
—
—
0
0
9
53
1.70
0.75
1.0
1.0
—
—
—
0
0
9
54
1.67
0.74
1.3
1.1
45.4
17.0
u/l
—
9
36
365
3426
1.09
0.72
4.3
3.9
4.0
2.0
ug/l
0.63
312
3072
16
109
1.47
0.71
1.1
1.1
—
—
—
0
0
23
308
0.74
0.69
1.9
1.6
—
—
—
0
0
67
566
1.19
0.69
2.1
2.3
12.4
14.6
nmol/l
1.33
57
493
21
282
0.74
0.65
1.8
1.6
6583.7
13047.3
e6/l
1.41
15
209
5
29
1.73
0.64
1.0
1.5
—
—
—
0
0
8
49
1.64
0.62
1.3
1.2
—
—
—
0
0
8
49
1.64
0.62
1.3
1.2
—
—
—
0
0
8
50
1.60
0.61
1.4
2.0
—
—
—
0
0
0
20
0.00
0.60
0.0
1.4
—
113.4
—
0
20
124
1117
1.12
0.57
2.6
2.5
5.0
7.6
ug/l
1.64
108
977
32
256
1.26
0.57
1.5
1.3
—
—
—
0
0
6
36
1.67
0.56
1.3
1.2
—
—
—
0
0
6
36
1.67
0.56
1.3
1.2
—
—
—
0
0
138
1518
0.90
0.56
7.2
6.8
—
—
—
0
0
16
116
1.38
0.54
1.3
1.0
3.7
2.7
u/ml
—
5
50
49
414
1.19
0.53
2.8
3.6
24.6
24.9
mmol/l
0.27
43
379
19
143
1.33
0.52
1.2
1.1
—
—
—
0
0
14
100
1.40
0.52
1.4
1.6
—
—
—
0
0
31
252
1.24
0.50
2.7
3.7
33.5
27.1
mg/l
0.37
20
160
12
85
1.42
0.47
1.8
1.5
—
—
—
0
0
137
1488
0.91
0.46
5.2
4.9
32.1
33.0
%
0.46
99
968
7
49
1.43
0.46
1.1
1.1
—
—
—
0
0
5
82
0.61
0.46
1.2
1.5
—
—
—
0
0
29
237
1.23
0.45
1.2
1.4
57.5
41.3
e6/l
0.15
24
192
30
248
1.21
0.43
1.2
1.8
1.8
4.6
iu/l
—
9
85
25
306
0.81
0.43
3.0
2.3
22.2
100.1
ug/min
1.93
11
192
36
304
1.19
0.42
1.6
1.6
1.7
0.1
iu/ml
—
6
62
5
32
1.56
0.42
2.4
1.6
—
—
—
0
0
8
58
1.38
0.41
1.0
1.0
—
—
—
0
0
0
15
0.00
0.41
0.0
1.3
—
—
—
0
0
0
15
0.00
0.41
0.0
1.0
—
—
—
0
0
31
261
1.19
0.38
3.6
3.3
0.8
0.8
nmol/l
0.31
26
200
12
155
0.77
0.33
1.1
1.5
—
—
—
0
0
195
1855
1.06
0.30
1.2
1.2
15.7
13.7
u/ml
0.12
58
701
11
85
1.30
0.28
4.9
2.4
14.3
13.2
%
2.19
11
85
18
150
1.20
0.26
1.2
1.9
810.9
3000.1
u/l
—
5
57
55
501
1.10
0.26
1.0
1.0
—
—
—
0
0
239
2476
0.96
0.23
3.6
4.2
1.0
1.0
kg/l
0.39
31
374
0
11
0.00
0.21
0.0
1.0
—
—
—
0
0
113
1072
1.06
0.21
1.4
1.7
1.4
1.5
%
0.74
95
915
12
145
0.83
0.21
1.2
1.5
61.3
62.7
%
—
6
95
5
43
1.16
0.21
1.2
1.1
99.2
265.5
iu/ml
—
5
43
0
13
0.00
0.21
0.0
1.4
—
—
—
0
0
0
13
0.00
0.21
0.0
1.0
—
—
—
0
0
29
260
1.12
0.19
1.3
1.1
—
—
—
0
0
29
322
0.90
0.19
1.4
1.3
—
—
—
0
0
22
247
0.89
0.17
1.5
1.6
—
—
—
0
0
10
82
1.22
0.17
1.4
1.2
—
—
—
0
0
7
63
1.11
0.17
1.0
1.0
—
—
—
0
0
28
309
0.90
0.17
1.6
1.7
—
—
—
0
0
20
224
0.89
0.15
1.1
1.2
185.3
227.7
miu/ml
—
8
97
9
82
1.10
0.15
1.1
1.0
—
—
—
0
0
73
694
1.05
0.14
1.6
1.8
—
—
—
0
0
9
108
0.83
0.13
1.4
1.6
—
—
—
0
0
16
142
1.13
0.12
1.0
1.1
—
16.8
—
0
8
5
48
1.04
0.09
1.0
1.2
—
—
—
0
0
5
60
0.83
0.08
1.4
1.2
—
—
—
0
0
259
2556
1.02
0.07
1.7
1.7
446.3
17782459.8
pmol/l
1.75
198
2092
9
85
1.06
0.07
1.1
1.1
—
—
—
0
0
9
104
0.86
0.06
1.4
1.5
—
—
—
0
0
9
104
0.86
0.06
1.4
1.5
—
—
—
0
0
9
104
0.86
0.06
1.4
1.5
—
—
—
0
0
9
104
0.86
0.06
1.4
1.5
—
—
—
0
0
9
105
0.86
0.06
1.3
1.1
—
—
—
0
0
64
622
1.03
0.06
1.5
1.7
—
—
—
0
0
29
277
1.05
0.05
1.4
1.5
—
—
—
0
0
275
2776
0.99
0.05
3.8
3.8
23.4
24.0
%
0.23
139
1297
12
110
1.09
0.05
1.8
1.5
—
—
—
0
0
146
1481
0.98
0.05
1.4
1.4
—
—
—
0
0
191
1926
0.99
0.03
2.8
2.7
0.7
0.7
ug/l
0.28
134
1294
11
102
1.08
0.03
1.7
2.2
3.2
2.2
u/field
—
5
38
19
184
1.03
0.00
1.6
1.5
—
—
—
0
0
10
96
1.04
0.00
1.1
1.1
—
—
—
0
0
32
317
1.01
0.00
1.7
1.4
—
—
—
0
0
0
8
0.00
0.00
0.0
1.4
—
—
—
0
0
0
8
0.00
0.00
0.0
1.3
—
—
—
0
0
0
9
0.00
0.00
0.0
1.0
—
—
—
0
0
6
63
0.95
0.00
1.0
1.2
—
—
—
0
0
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.2
—
7.5
—
0
6
6
59
1.02
0.00
1.7
1.7
0.3
3.1
u/field
—
6
44
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
6
62
0.97
0.00
1.0
1.2
—
—
—
0
0
6
66
0.91
0.00
3.5
1.7
17.5
18.8
nmol/l
—
6
55
0
5
0.00
0.00
0.0
1.8
—
11.7
—
0
5
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
9
93
0.97
0.00
1.1
1.1
—
5.4
—
0
5
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
0
7
0.00
0.00
0.0
1.3
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint THROMBOCYTAEMIA and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| THROMBOCYTAEMIA | 1.67 [1.48, 1.89] | < 0.001 |
| Birth year | 0.993 [0.98, 1.0] | 0.11 |
During the follow-up period (1.1.1998 — 31.12.2019), 986 out of 3701 females with THROMBOCYTAEMIA died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| THROMBOCYTAEMIA | 1.754 [1.51, 2.03] | < 0.001 |
| Birth year | 0.983 [0.97, 0.99] | < 0.001 |
During the follow-up period (1.1.1998 — 31.12.2019), 774 out of 2419 males with THROMBOCYTAEMIA died.
Mortality risk
Mortality risk for people of age
years, who have THROMBOCYTAEMIA.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.146% | 0.269% |
| 5 | 0.888% | 1.789% |
| 10 | 2.432% | 4.669% |
| 15 | 4.498% | 8.667% |
| 20 | 7.643% | 14.191% |
Relationships between endpoints
↥Index endpoint: THROMBOCYTAEMIA – Essential (haemorrhagic) thrombocythaemia
GWS hits: 12
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data